News & Updates

With the emergence of new subtypes of respiratory nosocomial infection and multi-drug resistant organisms (MDROs), better surveillance and infection prevention and control are necessary to address these healthcare challenges. In the MSD-sponsored scientific event entitled “Multidrug Resistant Infections: Updates on Diagnosis and Management” held on July 27, 2023, Dr Evelina Lagamayo, Clinical Pathologist and Microbiologist, Section Chief, Microbiology Department of Clinical Pathology, University of Santo Tomas Hospital; Dr Rontgene Solante, Chair, Adult Infectious Disease, Tropical Medicine, San Lazaro Hospital, and President of the Philippine College of Physicians; and Dr Carmenchu Villavicencio, Infection Control Chair of St. Luke’s Medicla Center Global City, as moderator discussed diagnostic tests for Enterobacterales and Pseudomonas aeruginosa, and the role of ceftolozane/tazobactam (ZERBAXA) in the treatment nosocomial pneumonia.

At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.

Probiotics have emerged as a pivotal adjunctive therapy for managing acute diarrhea. Recent advancements have unveiled the diverse utility of these bioactive agents beyond solely addressing diarrhea. Bacillus clausii (B. clausii), a widely utilized probiotic for acute diarrhea, particularly in pediatric cases, boasts multiple attributes that underpin its current applications and prospects. This article aims to delve into Bacillus clausii's physiological, probiotic, and immunomodulatory characteristics, shedding light on its potential indications through an exploration of ongoing research.

Rabeprazole sodium EC tab 20 mg and Lyo powd for IV inj (vial + 5 mL amp diluent) 20 mg x 10 mL x 1’s.

Cefepime HCl Powd for inj 1 g

Telmisartan, amlodipine besilate 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg and 80 mg/10 mg tablet

Rebamipide FC tab 100 mg